ARTL ARTELO BIOSCIENCES, INC.

Nasdaq artelobio.com


$ 1.80 $ -0.01 (-0.55 %)    

Thursday, 13-Nov-2025 10:47:12 EST
QQQ $ 611.16 $ -6.52 (-1.06 %)
DIA $ 479.22 $ -2.19 (-0.45 %)
SPY $ 675.61 $ -4.87 (-0.72 %)
TLT $ 89.86 $ 0.06 (0.07 %)
GLD $ 386.16 $ -1.13 (-0.29 %)
$ 1.8
$ 1.81
$ 1.76 x 340
$ 1.83 x 100
$ 1.80 - $ 1.81
$ 1.66 - $ 28.60
114,111
na
3.63M
$ 1.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-03-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-25-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-31-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 01-12-2022 11-30-2021 10-Q
17 11-29-2021 08-31-2021 10-K
18 07-12-2021 05-31-2021 10-Q
19 04-13-2021 02-28-2021 10-Q
20 01-14-2021 11-30-2020 10-Q
21 11-04-2020 08-31-2020 10-K
22 07-13-2020 05-31-2020 10-Q
23 04-13-2020 02-29-2020 10-Q
24 01-14-2020 11-30-2019 10-Q
25 11-25-2019 08-31-2019 10-K
26 07-15-2019 05-31-2019 10-Q
27 04-15-2019 02-28-2019 10-Q
28 01-14-2019 11-30-2018 10-Q
29 11-29-2018 08-31-2018 10-K
30 07-13-2018 05-31-2018 10-Q
31 04-16-2018 02-28-2018 10-Q
32 01-16-2018 11-30-2017 10-Q
33 11-29-2017 08-31-2017 10-K
34 07-21-2017 05-31-2017 10-Q
35 04-14-2017 02-28-2017 10-Q
36 01-10-2017 11-30-2016 10-Q
37 11-29-2016 08-31-2016 10-K
38 07-05-2016 05-31-2016 10-Q
39 04-01-2016 02-29-2016 10-Q
40 01-14-2016 11-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 artelo-biosciences-q3-eps-397-misses-082-estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(3.97) per share which missed the analyst consensus estimate of ...

 artelo-biosciences-announces-publication-of-peer-reviewed-article-the-emerging-role-of-fatty-acid-binding-protein-3-fabp3-in-cancers-in-drug-discovery-today

Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways ...

 artelo-biosciences-appoints-mark-spring-cfo-effective-nov-1

Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways ...

 artelo-biosciences-reports-phase-1-and-2-data-for-art2612-and-art2713-highlighting-safety-and-significant-weight-gain-in-cancer-anorexia-trial

ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed...

 artelo-biosciences-prices-20m-public-offering

SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutic...

 artelo-biosciences-announces-publication-of-new-preclinical-data-on-art1211-proprietary-cannabidioltetramethylpyrazine-cocrystal

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways...

 d-boral-capital-downgrades-artelo-biosciences-to-hold

D. Boral Capital analyst Jason Kolbert downgrades Artelo Biosciences (NASDAQ:ARTL) from Buy to Hold.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION